June is #NationalCancerSurvivorsMonth. At Century, we honor the courage and resilience of all cancer survivors and remain committed to expanding patient access to life-saving cell therapies so that one day all patients with cancer can become survivors. #CelebrateSurvivorship #CancerResearch
Century Therapeutics, Inc
Biotechnology
Philadelphia, Pennsylvania 21,853 followers
Harnessing the power of adult stem cells to develop curative therapies for cancer and autoimmune diseases
About us
Our genetically engineered, iPSC-derived cell products are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune and inflammatory diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune and inflammatory disease care. Please note Century Therapeutics does not solicit prospective Colleagues directly via Telegram (or other social media sites), or require potential candidates to make purchases of goods or services.
- Website
-
https://www.centurytx.com/
External link for Century Therapeutics, Inc
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- Philadelphia, Pennsylvania
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
Get directions
25 N 38th St
11th Floor
Philadelphia, Pennsylvania 19104, US
-
Get directions
260 Evans Way
Branchburg, New Jersey 08876, US
-
Get directions
201 Brookline Ave
Boston, Massachusetts 02215, US
Employees at Century Therapeutics, Inc
Updates
-
Today, we announced a poster presentation at the American Society of Clinical Oncology (ASCO)) annual meeting highlighting interim results from the ongoing Phase 1 ELiPSE-1 study of CNTY-101 in relapsed or refractory (R/R) #lymphoma. The poster showcases CNTY-101’s continued encouraging preliminary efficacy and manageable safety profile for with no observed DLTs or GvHD. Learn more: https://bit.ly/3RaEI3k #ASCO2024
-
-
We are looking forward to the American Society of Clinical Oncology (ASCO) Annual Meeting, where we will present interim data from our ongoing Phase 1 ELiPSE-1 study of CNTY-101 in relapsed or refractory (R/R) non-Hodgkin #lymphoma. We hope to see you at #ASCO24!
-
-
Century recognizes #LupusAwarenessMonth as part of the community dedicated to supporting those with Systemic Lupus Erythematosus. Recently, we hosted a booth at the LuCIN Community Meeting to further educate on the potential of CNTY-101 in #SLE and our planned CALiPSO-1 trial.
-
-
We’re excited to announce two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting. The preclinical data presented highlights advances in our #iPSC platform technology and programs, including the potential of CNTY-101 to treat B-cell driven #autoimmunediseases such as #SLE. Learn more: https://bit.ly/3QEr4VU #ASGCT2024
-
-
Today, we reported financial results and business highlights for Q1 2024. Read the full press release: https://bit.ly/4bcWoTU #biotech #investors
-
-
May is National Cancer Research Month. At Century, we are proud of our work to advance the research and development of next-generation iPSC-derived #celltherapies to provide meaningful treatments for people with #cancer. Learn more about our programs across #hematology, #oncology, and #autoimmune and #inflammatorydiseases: https://bit.ly/3M5EmJw #NCRM24
-
-
We are excited to attend Chardan 's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, where members of our management team will participate in a virtual fireside chat and panel. Learn more: https://bit.ly/49UR8m5 #ipsc #celltherapy
-
-
Today, we announced exciting plans to expand clinical development for our lead program, CNTY-101, a CD19-targeting iNK #celltherapy, into additional #autoimmunedisease indications. This expansion is supported by a $60 million private placement with a distinguished group of investors. Concurrently, we announced pipeline and platform enhancements through the acquisition of Clade Therapeutics. Learn more: https://bit.ly/43TNOGx
-
-
We are proud to present new preclinical data highlighting our iPSC-derived #celltherapy platform technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Read the full press release: https://bit.ly/4cOsnLa #AACR24 #ipsc
-